Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OptiNose, Inc.
  6. News
  7. Summary
    OPTN   US68404V1008

OPTINOSE, INC.

(OPTN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-31 pm EST
1.790 USD   +2.87%
08:14aOptiNose Appoints Ramy Mahmoud Chief Executive; Reiterates 2022 Revenue Outlook
MT
08:09aOptinose, Inc. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
07:00aOptinose Announces CEO Transition and Business Update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Optinose : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million (Form 8-K)

07/28/2021 | 08:04am EST
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020

Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million

Conference Call and Webcast to be held August 11, 2021 at 8:00 a.m. Eastern Time

YARDLEY, Pa., July 28, 2021- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $18.4 million for the three months ended June 30, 2021. This represents a 79% increase compared to the three months ended June 30, 2020, and a 67% increase compared to the three months ended March 31, 2021. The Company expects XHANCE net product revenue for the full year of 2021 to be at least $80 million.

In addition, the number of XHANCE prescriptions increased by 33% from 62,500 in the second quarter 2020 to 82,900 in the second quarter 2021 based on third-party prescription data and data from XHANCE preferred pharmacy network partners. XHANCE net revenue per prescription increased 35% from $164 in the second quarter 2020 to $221 in the second quarter 2021 based on preliminary second quarter net product revenue of $18.4 million.

The financial information included in this release is preliminary and is subject to change. The Company expects to report full financial results for the second quarter of 2021 and corporate updates before market open on Wednesday, August 11, 2021.

'We are pleased with the growth in demand for XHANCE and increased net product revenue per prescription based on preliminary second quarter net product revenue of $18.4 million,' stated CEO Peter Miller. 'We believe XHANCE is on-track for full year 2021 revenues to be at least $80 million and we look forward to providing a complete update of our recent commercial performance and drug development progress on the eleventh of August.'

Company to Host Conference Call
Members of the Company's leadership team will host a conference call starting at 8:00 a.m. Eastern Time on Wednesday, August 11, 2021 to discuss financial results and corporate updates.

To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until Wednesday, August 18, 2021 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID # 2867629. A


simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose's website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.comor follow us on Twitterand LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: preliminary XHANCE® net product revenue of $18.4 million for the quarter ended June 30, 2021 and growth rates over prior periods; net product revenue per prescription of $221 for the quarter ended June 30, 2021 based on preliminary XHANCE net product revenue of $18.4 million, and growth rates over prior periods; the Company's expectation that XHANCE net product revenue for the full year of 2021 will be at least $80 million; the Company's expectation to report full financial results for the second quarter of 2021 and corporate updates before market open on Wednesday, August 11, 2021; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives; and other future events. Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the potential for preliminary XHANCE net product revenue and XHANCE net product revenue per prescription for the quarter ended June 30, 2021, as well as growth rates over prior periods, to change in connection with the finalization of the Company's financial results for the second quarter of 2021;the extent and duration of the COVID-19 pandemic and its impact on the Company's business, results of operations and financial condition; physician and patient acceptance of XHANCE; the Company's ability to maintain adequate third-party reimbursement for XHANCE (market access); the Company's ability to grow XHANCE prescriptions and net revenues; unanticipated costs and expenses and the Company's ability to comply with the covenants and terms of its debt facility; and the risks, uncertainties and other factors discussed under the caption 'Item 1A. Risk Factors' and elsewhere in the Company's most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

Disclaimer

OptiNose Inc. published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 12:03:09 UTC.


ę Publicnow 2021
All news about OPTINOSE, INC.
08:14aOptiNose Appoints Ramy Mahmoud Chief Executive; Reiterates 2022 Revenue Outlook
MT
08:09aOptinose, Inc. : Results of Operations and Financial Condition, Change in Directors or Pri..
AQ
07:00aOptinose Announces CEO Transition and Business Update
AQ
2022Optinose, Inc. : Change in Directors or Principal Officers, Other Events, Financial Statem..
AQ
2022Optinose Names Paul Spence as Chief Commercial Officer
MT
2022Optinose, Inc. : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
2022Optinose Appoints Paul Spence as Chief Commercial Officer
AQ
2022OptiNose, Inc. Appoints Paul Spence as Chief Commercial Officer
CI
2022OptiNose Acting Chief Financial Officer Michele Janis to Depart
MT
2022Optinose, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on OPTINOSE, INC.
More recommendations
Financials (USD)
Sales 2022 76,1 M - -
Net income 2022 -73,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,04x
Yield 2022 -
Capitalization 197 M 197 M -
Capi. / Sales 2022 2,58x
Capi. / Sales 2023 2,23x
Nbr of Employees 191
Free-Float 57,4%
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,79 $
Average target price 5,60 $
Spread / Average Target 213%
EPS Revisions
Managers and Directors
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Joseph C. Scodari Independent Chairman
John C. Messina SVP-Clinical Development & Medical Affairs
Harry Sacks VP-Medical Affairs & Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OPTINOSE, INC.-5.95%191
JOHNSON & JOHNSON-8.29%423 546
ELI LILLY AND COMPANY-6.49%323 536
NOVO NORDISK A/S2.51%317 108
ROCHE HOLDING AG-0.79%275 846
MERCK & CO., INC.-4.38%268 980